Evolving landscape of first-line combination therapy in advanced renal cancer: a systematic review

Aly-Khan A. Lalani, Daniel Y. C. Heng, Naveen S. Basappa, Lori Wood, Nayyer Iqbal, Deanna McLeod, Denis Soulières and Christian Kollmannsberger

Abstract

Background: Renal cell carcinoma (RCC) is a common malignancy with approximately 30% of cases diagnosed at the advanced or metastatic stage. While single-agent vascular endothelial growth factor-targeted therapy has been a mainstay of treatment, data from multiple phase III trials assessing first-line immune checkpoint inhibitor (ICI) combinations have demonstrated a significant survival benefit.

Methods: A systematic search of the published and presented literature was performed to identify phase III trials assessing ICI combination regimens in RCC using search terms ‘immune checkpoint inhibitors’ AND ‘renal cell carcinoma,’ AND ‘advanced’.

Results: Six phase III trials showed significant benefits for ICI combinations compared with sunitinib. Nivolumab plus ipilimumab significantly improved overall survival (OS; median, 47.0 versus 26.6 months, hazard ratio [HR] = 0.68, 95% confidence interval [CI] = 0.58–0.81, \( p < 0.0001 \)) and progression-free survival (PFS; median 11.6 versus 8.3 months, HR = 0.73, 95% CI = 0.61–0.87, \( p = 0.0004 \)) in International Metastatic renal cell carcinoma Database Consortium intermediate and poor-risk patients. OS was also significantly improved for ICI plus tyrosine kinase inhibitor combinations regardless of risk, including pembrolizumab plus either axitinib (HR = 0.73, 95% CI = 0.60–0.88, \( p < 0.001 \)) or lenvatinib (HR = 0.66, 95% CI = 0.49–0.88, \( p = 0.005 \)) and nivolumab plus cabozantinib (HR = 0.66, 95% CI = 0.50–0.87, \( p = 0.003 \)). No new safety signals were identified.

Conclusions: Phase III first-line trials of ICI combinations showed survival benefits compared with a control arm of sunitinib. Global access to these combinations should be made available to patients with advanced RCC.

Keywords: advanced disease, combination therapy, immune checkpoint inhibitors, metastatic or locally targeted therapy, renal carcinoma, tyrosine kinase inhibitors

Introduction

Kidney cancer is a common malignancy with over 430,000 new cases reported worldwide in 2020 resulting in approximately 180,000 deaths.1 Renal cell carcinoma (RCC) represents the majority of kidney cancers (90–95%), with clear-cell RCC being the most common histological subtype.2,3 Approximately 30% of RCC cases are diagnosed at the advanced or metastatic stage and close to 80% of these patients have intermediate or poor-risk disease as per the International Metastatic renal cell carcinoma Database Consortium (IMDC) criteria.2–4 RCC is typified by inactivation of the von Hippel–Lindau tumor suppressor gene leading to high expression of the proangiogenic vascular endothelial growth factor (VEGF).5–7

Until recently, the mainstay of first-line therapy for advanced RCC involved the inhibition of...
angiogenesis with tyrosine kinase inhibitors (TKIs) against multiple receptors including those of VEGF (e.g. sunitinib and pazopanib). Historical benchmarks for median overall survival (OS) in the VEGF-targeted therapy era by IMDC risk groups have been 43, 23, and 8 months for favorable (IMDC 0), intermediate (IMDC 1 or 2), and poor-risk patients (IMDC \( \geq 3 \)), respectively. For years, the research landscape typically involved multiple alternative TKIs that also inhibit VEGF receptors including axitinib, cabozantinib, and lenvatinib, a monoclonal antibody (MoAb) that directly inhibits the function of VEGF (bevacizumab) and inhibition of the mammalian target of rapamycin (everolimus).

Immune checkpoint inhibitors (ICIs) include cytotoxic T lymphocyte antigen 4 inhibitors (e.g. ipilimumab) and those against the programmed cell death protein 1 (PD-1) in peripheral tissues (e.g. nivolumab and pembrolizumab) or its ligand (PD-L1) (e.g. atezolizumab and avelumab), some of which have recently become preferred for most first-line treatment of RCC. Therapies directed at VEGF or its receptor (VEGF-directed, anti-angiogenic monoclonal antibodies or TKIs) are thought to have immunomodulatory effects including the enhancement of immune cell infiltration by normalizing tumor vasculature holding the promise of synergistic activity. In the last 3 years, results from multiple phase III trials assessing the first-line benefits of ICI combinations involving dual ICIs or ICIs in combination with VEGF-directed therapies have become available. This review will consider the safety and efficacy of these regimens in newly diagnosed advanced RCC and provide practical clinical guidance on their use in this setting.

Methods
A search of published and presented literature was conducted to identify phase III trials with outcomes assessing ICI combination regimens in RCC. PubMed (all time to 19 March 2022), the proceedings from the 2019, 2020, and 2021 American Society of Clinical Oncology (ASCO) and the European Society for Medical Oncology (ESMO) annual meetings as well as the ASCO Genitourinary Cancers Symposium were searched using the key search terms ‘immune checkpoint inhibitors’ AND ‘renal cell carcinoma’, AND ‘advanced’ OR respective aliases. A supplemental bibliographic search of review articles and pooled/meta-analyses was also conducted. In addition, directed searches were performed after the database search cutoff date to ensure that the most up-to-date reports of eligible studies were considered.

Findings
The literature search identified a total of 628 records, resulting in a total of six eligible phase III trials (Preferred Reporting Items for Systematic Reviews and Meta-Analyses, Figure 1).

First-line ICI combinations
Six phase III trials assessed ICI combinations as first-line systemic treatment of advanced or metastatic RCC compared with the control arm of sunitinib (Table 1). One evaluated a dual ICI combination, another an ICI and anti-VEGF MoAb combination, and four ICI plus TKI combinations.

CheckMate 214 randomized 1096 patients of all risk groups 1:1 to receive nivolumab plus ipilimumab compared with sunitinib, with co-primary endpoints of OS, independent review committee (IRC)-assessed progression-free survival (PFS) and objective response rate (ORR) in IMDC intermediate and poor-risk patients (intermediate/poor risk, \( n = 847 \)), as well as additional exploratory endpoints among 249 favorable-risk patients. At a median follow-up of 25.2 months, initial findings showed a statistically significantly higher OS [median not yet reached (NR) versus 26.0 months, HR = 0.63, 95% confidence interval (CI) = 0.44–0.89 \( p < 0.001 \)] and increased PFS (median 11.6 versus 8.4 months, HR = 0.82, 95% CI = 0.64–1.05, \( p = 0.03 \)) for the ICI combination versus sunitinib, although PFS did not reach the pre-specified threshold for significance (\( p = 0.009 \)). With a longer median follow-up of 67.7 months, the ICI combination continued to show significant OS (median 26.0 versus 26.6 months, HR = 0.68, 95% CI = 0.58–0.81, \( p < 0.0001 \)), and PFS (median 11.6 versus
8.3 months, HR = 0.73, 95% CI = 0.61–0.87, p = 0.0004) improvements compared with sunitinib in intermediate/poor-risk population, with OS benefits also seen in the intent-to-treat (ITT) population (median 55.7 versus 38.4 months, HR = 0.72, 95% CI = 0.62–0.85, p < 0.0001) although not in favorable-risk patients (median 74.1 versus 68.4, HR = 0.94, 95% CI = 0.65–1.37, p = 0.77). An improved overall response rate (42% versus 27%) and long duration of responses (DoRs, median NR versus 19.7 months) were also seen in intermediate/poor-risk patients, with reduced ORR benefit in the ITT population (39% versus 32%) and which favored sunitinib in favorable-risk patients (30% versus 52%). Median time to confirmed deterioration was significantly longer for nivolumab plus ipilimumab versus sunitinib for all scores from the 19-item Functional Assessment of Cancer Therapy-Kidney Symptom Index (FKSI-19, p < 0.05). Discontinuations due to treatment-related adverse events (TRAEs) occurred in 21.8% versus 12.3% of patients, grade ≥3 TRAEs were reported in 46.6% and 63.9%, and treatment-related deaths occurred in 1.5% versus 0.7% of patients receiving nivolumab plus ipilimumab versus sunitinib (Table 2).

Figure 1. Preferred Reporting Items for Systematic Reviews and Meta-Analyses diagram. ASCO, American Society of Clinical Oncology; ASCO-GU, American Society of Clinical Oncology Genitourinary Cancers Symposium; ESMO, European Society for Medical Oncology.
Table 1. Phase III trials assessing efficacy of first-line ICI combinations in advanced RCC. IRC assessed the efficacy of outcomes in intent-to-treat populations of phase III ICI combination trials in previously untreated advanced RCC summarized and ordered by date of first report of results from initial analysis. Outcomes in specific IMDC risk populations were described when used in the primary endpoint analyses. Outcomes in PD-L1-positive subgroups summarized in text only.

| Trial name | NCT | Key characteristics IMDC risk score (%) PD-L1 status (%) | Regimen(s) | n    | Median follow-up, months [range] | IRC-assessed overall response rate, % (95% CI) | Median IRC-assessed duration of response, months (95% CI) | Median IRC-assessed PFS, months (95% CI) | Median OS, months (95% CI) |
|------------|-----|----------------------------------------------------------|------------|------|----------------------------------|-----------------------------------------------|----------------------------------------------------------|----------------------------------------|----------------------------|
| CheckMate 214 | NCT02231749 | Favorable [22.7] Intermediate [60.9] Poor [16.4] PD-L1 + [TC >= 1%] [21.9] | Nivolumab 3 mg/kg plus ipilimumab 1 mg/kg IV q3w x 4 then nivolumab 3 mg/kg IV q2w until progression | 550 | 67.7 [39 – 44] | 39 [35 – 44] | NR | 12.3 HR = 0.86 [0.73 – 1.01] p = 0.063 | 55.7 HR = 0.72 [0.62 – 0.85] p < 0.0001 |
| CheckMate 214 | NCT02231749 | Intermediate [78.7] Poor [21.3] PD-L1 + [TC >= 1%] [25.3] | Nivolumab 3 mg/kg plus ipilimumab 1 mg/kg IV q3w x 4 then nivolumab 3 mg/kg IV q2w until progression | 425 | 42 [37 – 47] | NR | 11.6 HR = 0.73 [0.61 – 0.87] p = 0.0004 | 47.0 HR = 0.68 [0.58 – 0.81] p < 0.0001 |
| IMmotion151 | NCT2420821 | Favorable [22.1] Intermediate [61.2] Poor [16.7] PD-L1 + [IC >= 1%] [39.6] | Atezolizumab 1200 mg IV q3w plus bevacizumab 15 mg/kg IV q3w | 454 | 32 [29 – 37] | 24.8 | 12.3 | 55.7 HR = 0.72 [0.62 – 0.85] p < 0.0001 |
| JAVELIN Renal 101 | NCT02684006 | Favorable [21.4] Intermediate [61.1] Poor [16.1] PD-L1 + [IC >= 1%] [63.2] | Avelumab 10 mg/kg IV q2w plus axitinib 5 mg PO BID | 442 | >19.3 Minimum: 28 | 52.5 [47.7 – 57.2] | 18.5 | 13.3 [0.57 – 0.83] p < 0.0001 | 36.1 HR = 0.91 [0.76 – 1.08] p = 0.27 |
| KEYNOTE-426 | NCT02853331 | Favorable [31.2] Intermediate [56.2] Poor [12.5] PD-L1 + [CPS >= 1%] [57.5] | Pembrolizumab 200 mg IV q3w x 35 plus axitinib 5 mg PO BID | 432 | 42.8 [35.6 – 50.6] | 60.4 [55.6 – 65.1] p < 0.0001 | 23.6 | 15.7 HR = 0.68 [0.58 – 0.80] p < 0.0001 | 45.7 HR = 0.73 [0.60 – 0.88] p < 0.001 |
| CheckMate 9ER | NCT03141177 | Favorable [22.4] Intermediate [57.8] Poor [19.8] PD-L1 + [TC > 1%] [25.5] | Nivolumab IV 240 mg q2w plus cabozantinib 40 mg PO QD until progression | 323 | 32.9 | 55.7 [50.1 – 61.2] p < 0.001 | 20.2 | 17.0 HR = 0.52 [0.43 – 0.64] p < 0.0001 | 37.7 HR = 0.70 [0.55 – 0.90] p < 0.001 |

(Continued)
| Trial name | NCT | IMDC risk score (%) | Regimen(s) | n | Median follow-up, months (range) | IRC-assessed overall response rate, % (95% CI) | Median IRC-assessed duration of response, months (95% CI) | Median IRC-assessed PFS, months (95% CI) | Median OS, months (95% CI) |
|------------|-----|---------------------|------------|---|----------------------------------|-----------------------------------------------|-------------------------------------------------|---------------------------------|-----------------------------|
| Sunitinib 50mg PO QD × 4w, q6w | 328 | 27.1 [22.4–32.3] | 11.5 | 8.3 | 34.3 |
| CLEAR | NCT02811861 | Favorable [32.6] | Pembrolizumab IV 200mg D1, q3w plus lenvatinib 20 mg PO QD q3w | 355 | 33.7 | 71.0 [66.3–75.7] | 25.8 | 23.9 | HR = 0.39 (0.32–0.49) \( p < 0.001 \) | NE HR = 0.72 (0.55–0.93) \( p = \) not reported |
| Everolimus 5mg PO QD q3w plus lenvatinib 18 mg PO QD q3w | 357 | 26.6 | 53.5 [48.3–58.7] | 16.6 | 14.7 | HR = 0.65 (0.53–0.80) \( p < 0.001 \) | NR | HR = 1.15 (0.88–1.5) \( p = 0.30 \) |
| Sunitinib 50mg PO QD × 4w, q6w | 357 | 33.4 | 36.1 [31.2–41.1] | 14.6 | 9.2 | NE |

*Co-primary endpoint was investigator-assessed PFS in the PD-L1-positive population (median, 11.2 versus 7.7 months, HR = 0.74, \( p = 0.0217 \)).

*At a median follow-up of 15 months.

**IRC assessed at a minimum follow-up of 13 months.

*Co-primary endpoints were IRC-assessed PFS and OS in the PD-L1-positive population (median, 13.8 versus 7.0 months, HR = 0.62, \( p = 0.0001 \); and NR versus 28.6 months, HR = 0.83, \( p = 0.13 \), respectively, at a minimum follow-up of 13 months.

*At the earlier follow-up of 18.1 months.

BID, twice daily; CI, confidence interval; CPS, combined positive score; DX, day X; HR, hazard ratio; IC, tumor-infiltrating immune cells; ICI, immune checkpoint inhibitor; IMDC, International Metastatic Renal Cell Carcinoma DATABASE Consortium; IRC, independent review committee; IV, intravenous; n, number of patients; NE, not estimable; NR, not yet reached; OS, overall survival; PD-L1, programmed death-ligand 1; PFS, progression-free survival; PO, taken orally; QD, once daily; qXw, every X weeks; RCC, renal cell carcinoma; TC, tumor cells.
Table 2. Safety outcomes from clinical trials assessing first-line ICI combinations in metastatic RCC.

| Treatment algorithm | Safety population, n | Overall TRAE in >1% | Any grade AE, n (%) | Grade ≥3 AEs, n (%) | AEs leading to discontinuation of any treatment, n (%) | AE- or treatment-associated deaths, n (%) | Select grade ≥3 TRAEs (any grade in >1%) |
|---------------------|----------------------|---------------------|---------------------|---------------------|-------------------------------------------------|----------------------------------------|--------------------------------------|
|                     |                      |                     |                     |                     |                                                 |                                        |                                      |
| Nivolumab + Ipilimumab + Nivolumab | 547                  | 443 (80.9)          | 443 (82.8)          | 443 (82.8)          | 411 (91.1)                                      | 66 (12.3)                             | Hypertension (10.4%)                  |
|                     |                      |                     |                     |                     |                                                 |                                        |                                      |
| Atezolizumab + Bevacizumab + Sunitinib | 535                  | 411 (96.1)          | 429 (96.1)          | 429 (96.1)          | 414 (95.4)                                      | 24 (5.3)                              | Hyperkalemia (3.8%)                   |
|                     |                      |                     |                     |                     |                                                 |                                        |                                      |
| Pembrolizumab + Axitinib + Sunitinib | 466                  | 423 (96.4)          | 423 (96.4)          | 423 (96.4)          | 413 (96.3)                                      | 37 (8.3)                              | Increased lipase (6.7%)               |
|                     |                      |                     |                     |                     |                                                 |                                        |                                      |
| Pembrolizumab + Axitinib + Sunitinib | 439                  | 413 (97.6)          | 413 (97.6)          | 413 (97.6)          | 309 (96.6)                                      | 59 (13.4)                             | Thrombocytopenia (5.2%)              |
| Pembrolizumab + Lenvatinib + Everolimus + Lenvatinib | 429                  | 309 (96.6)          | 309 (96.6)          | 309 (96.6)          | 298 (93.1)                                      | 63 (19.7)                             | Hypothyroidism (2.7%)                 |
| Pembrolizumab + Lenvatinib + Everolimus + Lenvatinib | 320                  | 341 (96.9)          | 341 (96.9)          | 341 (96.9)          | 347 (97.7)                                      | 341 (96.9)                            | Thrombocytopenia (5.2%)              |
| Pembrolizumab + Lenvatinib + Everolimus + Lenvatinib | 320                  | 313 (92.1)          | 313 (92.1)          | 313 (92.1)          | 313 (92.1)                                      | 313 (92.1)                            | Hypothyroidism (2.7%)                 |
| Pembrolizumab + Lenvatinib + Everolimus + Lenvatinib | 352                  | 252 (71.6)          | 252 (71.6)          | 252 (71.6)          | 259 (73.0)                                      | 259 (73.0)                            | Thrombocytopenia (5.2%)              |
| Pembrolizumab + Lenvatinib + Everolimus + Lenvatinib | 355                  | 200 (58.8)          | 200 (58.8)          | 200 (58.8)          | 200 (58.8)                                      | 200 (58.8)                            | Hypothyroidism (2.7%)                 |

AEs, adverse events; ALT, alanine aminotransferase; AST, aspartate aminotransferase; IO, immunotherapy; n, number of patients; PPE, Palmar-plantar erythrodysesthesia syndrome; RCC, renal cell carcinoma; TRAE, treatment-related adverse event.
compared with sunitinib. At median follow-ups of 15 and 24 months for PFS and OS, respectively, similar investigator-assessed ORRs and DoRs were observed between arms, with no statistically significant improvements seen in PFS or OS for the ICI plus VEGF-directed therapy combination compared with sunitinib. At a longer median follow-up of 32 months, no significant improvement in the co-primary endpoint of OS was seen in ITT patients (median OS, 36.1 versus 35.3 months, HR = 0.91, 95% CI = 0.76–1.08, p = 0.27, Table 1) or in patients with PD-L1-positive tumors (median OS, 38.7 versus 31.6 months, HR = 0.85, 95% CI = 0.64–1.13, p = not reported).

JAVELIN Renal 101 randomized 886 patients 1:1 to receive avelumab plus axitinib compared with sunitinib in patients with primarily PD-L1-positive tumors (63.2%). Co-primary endpoints were IRC-assessed PFS and OS among patients with PD-L1-positive tumors. With a minimum follow-up of 13 months, significant IRC-assessed PFS improvements were observed for the ICI combination over sunitinib in patients with tumors overexpressing PD-L1 and ITT patients, with a near doubling of ORRs and median DoRs not reported (Table 1). At a minimum follow-up of 28 months, there was no statistically significant OS improvement for the ICI combination over sunitinib (median OS, NE versus 37.8 months, HR = 0.79, 95% CI = 0.64–0.97, p = 0.012), although further follow-up is ongoing. Discontinuations due to TRAEs occurred in 7.6% versus 13.4% of patients, grade ≥3 TRAEs were reported in 56.7% and 55.4%, and treatment-related deaths occurred in 0.7% versus 0.2% of patients in the combination and sunitinib arms, respectively (Table 2).

KEYNOTE-426 randomized 861 patients 1:1 to receive the PD-1 inhibitor pembrolizumab plus axitinib compared with sunitinib. With a median follow-up of 30.6 months in the ITT population, statistically significant improvements for the ICI combination versus sunitinib were observed for the co-primary endpoint of IRC-assessed PFS (median 15.4 versus 11.1 months, HR = 0.71, 95% CI = 0.60–0.84, p < 0.0001). At a longer median follow-up of 42.8 months, PFS benefit remained significant (p < 0.0001), with significant benefits also demonstrated for the co-primary endpoint of OS (median 45.7 versus 40.1 months, HR = 0.73, 95% CI = 0.60–0.88, p < 0.001) and ORR (60.4% versus 39.6%, p < 0.0001). The median DoR was numerically improved (23.6 versus 15.3 months, p = not reported) for the ICI combination compared with sunitinib. Changes in mean FKSI-disease-related symptom scores from baseline to 30 weeks were similar for pembrolizumab plus axitinib versus sunitinib (−0.8 versus −0.3), with the −0.5 difference below the threshold for minimally important difference (±3 points). Discontinuation of any trial drug due to TRAEs occurred in 25.9% versus 10.1%, grade ≥3 TRAEs were reported in 62.9% versus 58.1%, and treatment-related deaths occurred in 0.9% versus 1.6% of patients receiving pembrolizumab plus axitinib compared with sunitinib (Table 2). CheckMate 9ER randomized 651 patients 1:1 to receive the PD-1 inhibitor nivolumab plus cabozantinib compared with sunitinib. With a median follow-up of 18.1 months, statistically significant benefits were seen in the primary endpoint of IRC-assessed PFS for nivolumab plus cabozantinib versus sunitinib in ITT patients (median PFS, 16.6 versus 8.3 months, HR = 0.51, 95% CI = 0.41–0.64, p < 0.001), as well as in the key secondary endpoint of OS (median OS, NR versus NR, HR = 0.60, 98.9% CI = 0.40–0.89, p = 0.001; Table 1), which persisted with a longer median follow-up of 32.9 months (median OS, 37.7 versus 34.3 months, HR = 0.70, 95% CI = 0.55–0.90, p = NR). Initial IRC-assessed ORR was also significantly improved for the combination (55.7% versus 27.1%, 95% CI = 21.7–35.6, p < 0.001), with median DoRs of 20.2 versus 11.5 months. Compared with sunitinib, nivolumab plus cabozantinib was associated with improvements in FKSI-19 total score (median time to first deterioration 6.24 versus 3.48 months, HR = 0.70, 95% CI = 0.56–0.86, nominal p = 0.0007). Discontinuation of any trial drug due to AEs occurred in 19.7% of patients receiving nivolumab plus cabozantinib and in 16.9% of patients receiving sunitinib, and grade ≥3 AEs were reported in 60.6% and 50.9% of patients, respectively. One death attributed to treatment was reported in the combination arm (0.3% of patients) and two occurred in the sunitinib group (0.6%).
CLEAR randomized 1069 patients 1:1:1 to receive pembrolizumab or everolimus plus lenvatinib, with both combinations compared with sunitinib. At a median follow-up of 26.6 months, the primary endpoint of IRC-assessed PFS statistically significantly favored both the pembrolizumab (median PFS, 23.9 versus 9.2 months, HR = 0.39, 95% CI = 0.32–0.49, p < 0.001; Table 1) and everolimus combinations (median PFS, 14.7 versus 9.2 months, HR = 0.65, 95% CI = 0.53–0.80, p < 0.001) compared with sunitinib.29 At a later median follow-up of approximately 33.5 months, median OS was not estimable although statistically significantly favored the pembrolizumab combination (HR = 0.72, 95% CI = 0.55–0.93, p = not reported).38 At the earlier follow-up, OS was not improved for the everolimus combination (HR = 1.15, 95% CI = 0.88–1.50, p = .30), IRC-assessed ORRs were 71.0%, 53.5%, and 36.1%, and median DoRs were 25.8, 16.6, and 14.6 months in the pembrolizumab, everolimus, and sunitinib arms, respectively.29 Pembrolizumab plus lenvatinib showed significant improvements in median time until definitive deterioration compared with sunitinib (30.8 versus 27.0 months, p < 0.01) using FKSIdisease-related symptom scores.49 Discontinuation of any treatment due to TRAEs occurred in 37.2% and 27.0% receiving pembrolizumab and everolimus versus 14.4% of patients receiving sunitinib, and grade ≥3 TRAEs were reported in 71.6% and 73.0% of patients versus 58.8% in the control arm. Treatment-related deaths occurred in 1.1% and 0.8% versus 0.3% of patients receiving the pembrolizumab and everolimus combinations versus sunitinib (Table 2).

Discussion

What is the clinical benefit of ICI combination therapy in the first-line treatment of advanced RCC?

Preferred approaches for the first-line treatment of advanced RCC have shifted from TKI monotherapy, such as sunitinib or pazopanib, to combination strategies for most patients.9,10 Six phase III trials evaluating ICI combinations compared to sunitinib have been reported, including one assessing a dual ICI combination30 and five assessing combinations of an ICI plus an antiangiogenic agent using either a MoAb32 or a TKI.27–29 At median follow-ups of approximately 20–30 months, neither of the PD-L1 combinations, atezolizumab plus bevacizumab from IMmotion151 nor avelumab plus axitinib from JAVELIN Renal 101 demonstrated OS benefit compared to sunitinib,34,35 although the final survival analyses of JAVELIN Renal 101 are awaited.35 The rest of this discussion will therefore focus on results from PD-1 combinations, noting that these data should be interpreted in the context that trials have been reported at different timepoints of mature follow-up and that differences exist between trials with regard to IMDC risk group populations studied.

At a median follow-up of 67.7 months, the dual ICI combination of nivolumab plus ipilimumab resulted in a significant 32% reduction in risk of death in intermediate/poor-risk patients and a 28% reduction in the risk of death in ITT patients compared with sunitinib,33 although the rates of discontinuation of any treatment due to toxicity were higher for the combination (21.8% versus 12.3%).30 A similar benefit was seen for the PD-1 inhibitor, nivolumab, plus cabozantinib. At a median follow-up of approximately 24 months, the nivolumab combination reduced the risk of death by 34% (p = 0.003) and the risk of progression by 48% (p < 0.0001) in CheckMate 9ER. These benefits were coupled with comparable rates of discontinuation due to toxicity compared with sunitinib (19.7% versus 16.9%).

Benefits were also seen for the PD-1 inhibitor pembrolizumab plus TKI combinations. At a median follow-up of 30.6 months, pembrolizumab plus axitinib reduced the risk of death by 32% (p = 0.003) and risk of progression by 29% (p < 0.001) compared with sunitinib in KEYNOTE-426.31 Similar outcomes were also seen when pembrolizumab was combined with lenvatinib in the CLEAR study. At a median follow-up of approximately 34 months, the pembrolizumab combination reduced the risk of death by 28% compared with sunitinib (p = not reported) and the risk of progression by 61% (p < 0.001) at an earlier median follow-up of approximately 27 months.39,38 Improvements in OS seen in the KEYNOTE-426 and CLEAR studies were apparent despite the greater use of subsequent therapy in the sunitinib compared with experimental arms.46,47 Rates of discontinuation due to toxicity were higher for both pembrolizumab plus axitinib (25.9% versus 10.1%)31 and pembrolizumab plus lenvatinib (37.2% versus 14.4%) compared with sunitinib.29
In the absence of head-to-head trial comparisons, response outcomes may help refine selection between dual ICI or PD-1 inhibitor plus TKI combinations. The ORR reported for the dual ICI combination was 39% with an 18.2% rate of progressive disease,\(^48\) while ORRs for PD-1 inhibitor plus TKI combinations were higher, ranging from 55.7% to 71.0%.\(^{28,29,31}\) The highest ORR was reported for pembrolizumab plus len-vatinib with rates of progressive disease ranging from 5.4% to 11.3%.\(^{28,29,31}\) A similar pattern was seen for complete responses, which ranged from 8% to 10%.\(^{28-31}\) DoRs can also be an important therapeutic consideration, potentially affording patients long-term benefit. DoRs for the PD-1 inhibitor plus TKI combinations ranged from 20 to 26 months,\(^{28,29,31}\) while the most durable responses were observed using the dual ICI combination, with the median DoR NR at a median follow-up of 67.7 months.\(^{33}\) Furthermore, conditional survival data in intermediate/poor-risk patients treated with nivolumab/Ipilimumab showed a substantial increase in the percent probability of remaining progression-free for an additional 2 years beyond randomization (36%) compared with 3 years following randomization (90%), suggesting that responding patients have durable progression-free benefits. In patients with high tumor burden or aggressive course of disease where arresting tumor growth is clinically urgent and progression can be immediately catastrophic, an upfront approach using a PD-1 inhibitor plus a TKI may be preferred based on low rates of progressive disease seen with these regimens. All treatment decisions should consider both the evidence and patient preference and should be made in close collaborations with their physician.

**What is the safety of ICI combination therapy in the first-line treatment of advanced RCC?**

TKIs are commonly associated with hypertension, diarrhea, palmar-plantar erythrodysesthesia (PPE) and fatigue, and sunitinib generally requires administration daily for 4 weeks out of 6 weeks, which can increase toxicity.\(^{28-31}\) Any grade TRAEs rates for sunitinib ranged from 82.8% to 97.6% with grade \(\geq 3\) TRAEs ranging from 50.9% to 63.9%. In studies demonstrating an OS gain, the addition of a PD-1 inhibitor to a TKI increased grade \(\geq 3\) TRAEs by 4.5–12.8%,\(^{28,31}\) with the smallest increase seen when pembrolizumab was added to axitinib.\(^{31}\) In contrast, the combination of nivolumab plus ipilimumab decreased grade \(\geq 3\) AEs by 17.3% compared with sunitinib, with significantly longer time to confirmed deterioration for the ICI combination (FKSI-19, \(p < 0.05\)).\(^{40}\) Furthermore, treatment-free survival after the dual ICI combination was over twice that of sunitinib for intermediate/poor-risk (6.9 versus 3.1 months) and three times as long for favorable-risk patients (11.0 versus 3.7 months), suggesting that the ICI combination could allow for more treatment breaks.\(^{50}\) However, acute immune-related AEs were observed that required careful monitoring and carry both the risk of treatment discontinuation and ongoing management for persistent complications.\(^{30}\) Overall, however, the safety profile of the dual ICI combination was consistent with previous studies in RCC and other tumor types,\(^{51-55}\) with dose delays, rapid diagnostic workups, appropriate timing, and the use of glucocorticoids (28.7% of patients received \(\geq 40\) mg prednisone daily or equivalent) to manage any grade treatment-related select AEs.\(^{48}\) Patient-reported outcomes were similar or significantly improved for PD-1 inhibitor plus TKI combinations compared with sunitinib.\(^{44,45}\)

Figure 2(a) depicts grade 1/2 and grade \(\geq 3\) TRAEs of PD-1 inhibitor plus TKI combinations that were shown to prolong survival.\(^{28,29,43}\) Toxicity profiles were relatively consistent across combinations, with hypertension, diarrhea, and PPE being the most common grade \(\geq 3\) TRAEs, despite steroid use in 29% and 21% of patients in the CheckMate 214 and CheckMate 9ER trials, respectively.\(^{48,56}\) When the mean toxicity rates for the PD-1 inhibitor plus TKI combinations were plotted against those of the dual ICI combinations (Figure 2(b)), higher rates of hypertension, PPE, diarrhea, dysphonia, hypothyroidism, stomatitis, and decreased appetite were observed while the ICI combinations were associated with higher rates of pruritis and rash.\(^{27-31}\)

**Do some first-line patients benefit more from ICI combinations than others?**

Results from first-line trials show that ICI combinations significantly improved OS in patients with advanced RCC, although some IMDC risk groups benefited more than others. Results from subgroup analyses must be interpreted with caution as outcomes may be influenced by imbalances in baseline characteristics and studies were not designed to compare outcomes in these subgroups. IMDC risk subgroup outcomes were available for five trials (CheckMate 214, JAVELIN...
Renal 101, KEYNOTE-426, CheckMate 9ER, and CLEAR), which reported outcomes for intermediate/poor-risk patients representing between 66% and 78% of the ITT populations. When assessing intermediate and poor-risk groups, OS favored ICI combinations for all combinations, with relatively tight confidence intervals that did not cross unity (Figure 3(a)).

In intermediate-risk patients, OS favored ICI combinations but the benefit was less pronounced with CIs crossing unity in CheckMate 9ER. When assessing the favorable-risk patients, this population appeared to representing between 22% and 33% of the included studies. Benefit in these patients was less clear with OS favoring ICI combinations in some studies and sunitinib in others, with CIs that were wide and crossed unity. Assessment of OS benefit in favorable-risk patient subgroups requires longer follow-up, although initial PFS benefits appear promising for nivolumab plus cabozantinib (HR = 0.58), avelumab plus axitinib (HR= 0.63) and pembrolizumab plus axitinib (HR= 0.76). ICI combination outcomes vary based on IMDC-risk, with the greatest benefit observed for poor-risk and intermediate/poor-risk patients.

Sarcomatoid differentiation, levels of tumor PD-L1 expression, and nephrectomy status have been assessed as factors to identify patients who may benefit from ICI combination therapy. Five trials evaluated OS in patients with tumors having sarcomatoid differentiation (CheckMate214, IMmotion151, KEYNOTE-426, CheckMate9 ER and CLEAR), with approximately 7%–16% of patients in this subgroup across trials. Survival outcomes generally favored ICI combinations compared with sunitinib, with the greatest benefit associated with the dual ICI combination and nivolumab plus cabozantinib (Figure 3(b)). Five of the six ICI combination trials reported outcomes based on PD-L1 expression.

Figure 2. Select TRAE rates in phase III trials of ICI combinations. (a) TKI combination trials (ICI + TKI). (b) Average ICI + TKI and ICI + ICI TRAE rates.

ICI, immune checkpoint inhibitor; Nivo + Cabo, nivolumab plus cabozantinib; Nivo + Ipi, nivolumab plus ipilimumab; Pembro + Axi, pembrolizumab plus axitinib; Pembro + Lenva, pembrolizumab plus lenvatinib; PPE, palmar-plantar erythrodysesthesia; TKI, tyrosine kinase inhibitor; TRAE, treatment-related adverse event.
Table 3. Ongoing Phase III Clinical Trials of Immune Checkpoint Inhibitor Combination Therapy in Early Stage or First-Line Advanced Renal Cell Carcinoma.

| Experimental agent(s) | Trial ID (NCT#) | Key eligibility criteria | Experimental regimen | Comparator | Primary endpoint(s) | Estimated PCD |
|-----------------------|-----------------|--------------------------|----------------------|------------|---------------------|---------------|
| **Early adjuvant**    |                 |                          |                      |            |                     |               |
| Nivolumab             | CheckMate 914 (NCT03138512) | Clear-cell component tumors with or without sarcomatoid features and of high risk of relapse | Nivolumab + Ipilimumab | Placebo | DFS | April 2023 |
| Ipilimumab            |                 |                          |                      |            |                     |               |
| Durvalumab            | RAMPART(NCT03288532) | Any cell type component tumors with high or intermediate risk of relapse | Durvalumab versus Durvalumab + Tremelimumab | Active monitoring | DFS, OS | July 2024 |
| Tremelimumab          |                 |                          |                      |            |                     |               |
| Pembrolizumab         | MK-6482-022 (NCT05239728) | Clear-cell component tumors with or without sarcomatoid features with high or intermediate risk of relapse | Belzutifan + Pembrolizumab | Pembrolizumab + Placebo | DFS | October 2027 |
| Belzutifan            |                 |                          |                      |            |                     |               |
| **Advanced first line** |                 |                          |                      |            |                     |               |
| Nivolumab             | CA045002 (NCT03729245) | Clear-cell component histology with or without sarcomatoid features | Bempegaldesleukin + Nivolumab | Sunitinib or Cabozantinib | ORR, OS | December 2021 |
| Bempegaldesleukin     |                 |                          |                      |            |                     |               |
| Toripalimab           | JS001-036-III- RCC (NCT04394975) | Clear-cell component tumors with or without sarcomatoid features | Toripalimab + Axitinib | Sunitinib | PFS | June 2023 |
| Axitinib              |                 |                          |                      |            |                     |               |
| Nivolumab             | COSMIC-313 (NCT03937219) | Clear-cell component tumors of intermediate or poor risk | Cabozantinib + Nivolumab + Ipilimumab then Cabozantinib + Nivolumab | Pembrolizumab + Placebo then Placebo + Nivolumab | PFS | November 2021 |
| Ipilimumab            |                 |                          |                      |            |                     |               |
| Cabozantinib          |                 |                          |                      |            |                     |               |
| Pembrolizumab         | TQB2450-III-07 (NCT04523272) | Clear-cell component | TQB2450 + Anlotinib | Sunitinib | PFS | June 2023 |
| Anlotinib             |                 |                          |                      |            |                     |               |
| Pembrolizumab         | MK-6482-012 (NCT04736706) | Clear-cell component | Pembrolizumab + Belzutifan + Lenvatinib versus Pembrolizumab/ Quavonlimab + Lenvatinib | Pembrolizumab + Lenvatinib | PFS, OS | October 2026 |
| Belzutifan            |                 |                          |                      |            |                     |               |
| Lenvatinib            |                 |                          |                      |            |                     |               |
| Nivolumab             | PDIGREE(NCT03793166) | Clear-cell component tumors with or without sarcomatoid features | Nivolumab + Cabozantinib | Nivolumab | OS | September 2021 |
| Cabozantinib          |                 |                          |                      |            |                     |               |
| Nivolumab             | Phase IIIb CA209-8Y8 (NCT03873402) | Clear-cell component tumors with or without sarcomatoid features and of intermediate or poor risk by IMDC | Nivolumab + Ipilimumab + Nivolumab + Cabozantinib | Nivolumab + Ipilimumab then Nivolumab + Cabozantinib | PFS, ORR | August 2021 |
| Ipilimumab            |                 |                          |                      |            |                     |               |

Ongoing (trials that are actively recruiting for which efficacy outcomes are not yet available) Phase III trials of ICI combination regimens for treatment of early or advanced RCC listed at CT.gov on 22 April 2021 are ordered by treatment setting and estimated primary completion date. DFS, disease-free survival; ICI, immune checkpoint inhibitor; IMDC, International Metastatic RCC Database Consortium; ORR, objective response rate; OS, overall survival; PCD, primary completion date; PFS, progression-free survival; RCC, renal cell carcinoma.
expression status, with no association detected between PD-L1 status and survival (Figure S1). Four trials reported outcomes based on nephrectomy status, with none showing a clear association between this variable and survival.27,28,31,57,62

What are the factors in selecting among first-line ICI combination therapies for advanced RCC?

Four ICI combinations have demonstrated an OS benefit compared to sunitinib in patients with first-line advanced RCC and an ECOG PS $\leq 2$,27,28,33,35–37 although five have shown either PFS or OS benefits and are currently approved by the United States Food and Drug administration and/or the European Medicines Agency (Table S2). Treatment selection should incorporate patient and disease characteristics, IMDC risk status, treatment history prior to the onset of advanced disease, and eligibility for immunotherapy. For patients with an intermediate/poor IMDC risk, nivolumab plus ipilimumab may be a good option due to the strong and durable OS benefit in patients suitable for combination ICI therapy. All three ICI plus TKI options, pembrolizumab plus axitinib, pembrolizumab plus lenvatinib, and nivolumab plus cabozantinib are also life-prolonging options and offer higher ORRs with the lowest progressive disease rates, although they may be associated with chronic toxicities due to extended TKI use. For patients with a favorable IMDC risk, subgroup analyses suggest that further follow-up is required (Figure 3(a)) and nivolumab plus ipilimumab has not been approved for this subgroup in many jurisdictions.

What is the state of the future for combination strategies in RCC?

The role of ICI combinations is rapidly evolving, with multiple-phase III trials underway for both advanced RCC and for adjuvant treatment (Table 3). In advanced disease, established ICI plus TKI combinations are being assessed in clear-cell component tumors with or without sarcomatoid features (PDIGREE – NCT03793166) while new ICI combinations are also being evaluated.
such as the TKI combinations TQB2450 plus anlotinib (NCT04523272) and toripalimab plus axitinib (NCT04394975), in addition to the PEGylated interleukin-2 bempegaldesleukin plus nivolumab (NCT03729245). The future may shift again, with triplet strategies being evaluated first-line globally using established ICIs in COSMIC-313 (NCT03937219) and belzutifan, a selective small molecule inhibitor of hypoxia-inducible factor-2α, in MK-6482-012 (NCT04736706). In the adjuvant setting, dual ICI combinations including nivolumab plus ipilimumab (NCT03138512), durvalumab plus tremelimumab (NCT03288532), and pembrolizumab plus belzutifan (NCT03239728) are being assessed as in patients with intermediate/high risk of relapse. The role of ICI combinations is rapidly evolving and ongoing trials will inform optimal use across the disease trajectory.

**Summary**
Recent outcomes from first-line ICI combination trials have reported OS benefit compared to sunitinib in advanced RCC, all of which present efficacious treatment options in this setting depending on IMDC risk status. The dual ICI combination nivolumab plus ipilimumab demonstrated a robust and durable OS benefit with a relatively favorable safety profile compared to sunitinib in IMDC intermediate or poor-risk patients. Pembrolizumab plus axitinib or lenvatinib and nivolumab plus cabozantinib demonstrated an OS benefit in patients regardless of IMDC risk. Research into novel therapies and to elucidate the role of ICI combinations in earlier lines of treatment are ongoing and will help inform the optimal role of these combinations in this rapidly evolving treatment landscape.

**Ethics approval and consent to participate**
Not applicable.

**Consent for publication**
Not applicable.

**Author contributions**
**Aly-Khan A. Lalani:** Conceptualization; Data curation; Formal analysis; Methodology; Project administration; Resources; Supervision; Validation; Writing – original draft; Writing – review & editing.

**Naveen S. Basappa:** Data curation; Methodology; Validation; Writing – review & editing.

**Lori Wood:** Data curation; Methodology; Validation; Writing – review & editing.

**Nayyer Iqbal:** Data curation; Methodology; Validation; Writing – review & editing.

**Deanna McLeod:** Conceptualization; Data curation; Formal analysis; Funding acquisition; Methodology; Project administration; Resources; Supervision; Validation; Writing – original draft; Writing – review & editing.

**Denis Soulières:** Data curation; Methodology; Validation; Writing – review & editing.

**Christian Kollmannsberger:** Conceptualization; Data curation; Methodology; Resources; Supervision; Validation; Writing – review & editing.

**ORCID iD**
Aly-Khan A. Lalani [https://orcid.org/0000-0002-9907-9112](https://orcid.org/0000-0002-9907-9112)

**Acknowledgements**
We would like to thank Ilidio Martins and Paul Card from Kaleidoscope Strategic Inc. for their research and editorial support as well as Eisai Limited (CA), Ipsen Canada, Merck Canada Inc. and Pfizer Canada Inc. for funding this review.

**Funding**
The authors disclosed receipt of the following financial support for the research, authorship, and/or publication of this article: This work was supported by unrestricted educational grants from Eisai Limited (CA), Ipsen Canada, Merck Canada Inc. and Pfizer Canada Inc. No discussion or viewing of review content was permitted with sponsors at any stage of review development.

**Competing Interests**
A-K.A.L. has received honoraria from AbbVie, Astellas, Bayer, BMS, Eisai, Ipsen, Janssen, Merck, Novartis, Pfizer, Roche, and TerSera, and received research funding from BMS, BioCanRx, Novartis, Roche, Ipsen, and EMD Serrono.

D.Y.C.H. has served in consultancy or advisory role for Pfizer, Novartis, BMS, Merck, Ipsen, Exilexis, and Eisai; and has received research funding from Pfizer, Novartis, BMS, Merck, and Ipsen.
N.S.B. has served in consultancy or advisory role for Merck, BMS, Eisai, Ipsen, EMD Serono, Roche, and Pfizer; and has received honoraria from Merck, BMS, Eisai, Ipsen, EMD Serono, Roche, and Pfizer.

L.W. has received research funding from Merck, Roche, BMS, Astrazeneca, and Pfizer.

N.I. has nothing to disclose.

D.M. has nothing to disclose.

D.S. has served in consultancy or advisory role for Merck, Novartis, Pfizer, Adlai-Nortye, and BMS; has received honoraria from Merck, BMS, Pfizer, Adlai-Nortye; and has received research funding from Pfizer, BMS, Merck, GSK, and Adlai-Nortye

C.K. has served in consultancy or advisory role for Pfizer, Merck, Eisai, Ipsen, EMD, Astellas, Janssen, Bayer, and BMS, and has received honoraria from BMS, Ipsen, Astellas, Merck, and Pfizer.

Disclaimer
This review was prepared according to ICMJE standards with editorial assistance from Kaleidoscope Strategic Inc.

Availability of data and materials
Not applicable.

Supplemental material
Supplemental material for this article is available online.

References
1. Sung H, Ferlay J, Siegel RL, et al. Global cancer statistics 2020: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin 2021; 71: 209–249.

2. Padala SA, Barsouk A, Thandra KC, et al. Epidemiology of renal cell carcinoma. World J Oncol 2020; 11: 79.

3. Jonasch E, Walker CL and Rathmell WK. Clear cell renal cell carcinoma ontogeny and mechanisms of lethality. Nat Rev Nephrol 2021; 17: 245–261.

4. Heng DY, Xie W, Regan MM, et al. External validation and comparison with other models of the International Metastatic Renal-Cell Carcinoma Database Consortium prognostic model: a population-based study. Lancet Oncol 2013; 14: 141–148.

5. Jacobsen J, Grankvist K, Rasmussen T, et al. Expression of vascular endothelial growth factor protein in human renal cell carcinoma. BJU Int 2004; 93: 297–302.

6. Rini BI. Vascular endothelial growth factor-targeted therapy in renal cell carcinoma: current status and future directions. Clin Cancer Res 2007; 13: 1098–1106.

7. Kaelin WG. The von Hippel-Lindau tumor suppressor protein and clear cell renal carcinoma. Clin Cancer Res 2007; 13: 680s–684s.

8. Rassy E, Flippot R and Albige L. Tyrosine kinase inhibitors and immunotherapy combinations in renal cell carcinoma. Ther adv Med Oncol 2020; 12: 175835920907504.

9. Moran M, Nickens D, Adcock K, et al. Sunitinib for metastatic renal cell carcinoma: a systematic review and meta-analysis of real-world and clinical trials data. Target Oncol 2019; 14: 405–416.

10. FDA.gov. SUTENT® (sunitinib malate), https://www.accessdata.fda.gov/drugsatfda_docs/label/2014/021938s027lbl.pdf (accessed 11 May 2021).

11. Escudier B, Porta C, Schmidinger M, et al. Renal cell carcinoma: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. Ann Oncol 2019; 30: 706–720.

12. Suyama K and Iwase H. Lenvatinib: a promising molecular targeted agent for multiple cancers. Cancer Control 2018; 25: 1073274818789361.

13. Del Vecchio SJ and Ellis RJ. Cabozantinib for the management of metastatic clear cell renal cell carcinoma. J Kidney Cancer VHL 2018; 5: 1.

14. Bellesoeur A, Carton E, Alexandre J, et al. Axitinib in the treatment of renal cell carcinoma: design, development, and place in therapy. Drug Des Devel Ther 2017; 11: 2801.

15. Garcia J, Hurwitz HI, Sandler AB, et al. Bevacizumab (Avastin®) in cancer treatment: a review of 15 years of clinical experience and future outlook. Cancer Treat Rev 2020; 86: 102017.

16. Meskawi M, Valdivieso R, Dell’Oglio P, et al. The role of everolimus in renal cell carcinoma. J Kidney Cancer VHL 2015; 2: 187.

17. Brown LC, Desai K, Zhang T, et al. The immunotherapy landscape in renal cell carcinoma. BioDrugs 2020; 34: 733–748.

18. Aggen DH, Drake CG and Rini BI. Targeting PD-1 or PD-L1 in metastatic kidney cancer:
combination therapy in the first-line setting. *Clin Cancer Res* 2020; 26: 2087–2095.

19. Motzer RJ, Escudier B, McDermott DF, et al. Nivolumab versus everolimus in advanced renal-cell carcinoma. *N Engl J Med* 2015; 373: 1803–1813.

20. McDermott DF, Huseni MA, Atkins MB, et al. Clinical activity and molecular correlates of response to atezolizumab alone or in combination with bevacizumab versus sunitinib in renal cell carcinoma. *Nat Med* 2018; 24: 749–757.

21. Motzer RJ, Rini BI, McDermott DF, et al. Nivolumab for metastatic renal cell carcinoma: results of a randomized phase II trial. *J Clin Oncol* 2015; 33: 1430.

22. Motzer RJ, Jonasch E, Boyle S, et al. NCCN Guidelines insights: kidney cancer, version 1.2021: featured updates to the NCCN Guidelines. *J Natl Compr Cancer Netw* 2020; 18: 1160–1170.

23. Tenold M, Ravi P, Kumar M, et al. Current approaches to the treatment of advanced or metastatic renal cell carcinoma. *Am Soc Clin Oncol Educ Book* 2020; 40: 187–196.

24. Roland CL, Lynn KD, Toombs JE, et al. Cytokine levels correlate with immune cell infiltration after anti-VEGF therapy in preclinical mouse models of breast cancer. *PLoS One* 2009; 4: e7669.

25. Furukawa K, Nagano T, Tachihara M, et al. Interaction between immunotherapy and antiangiogenic therapy for cancer. *Molecules* 2020; 25: 3900.

26. Lee WS, Yang H, Chon HJ, et al. Combination of anti-angiogenic therapy and immune checkpoint blockade normalizes vascular-immune crosstalk to potentiate cancer immunity. *Exp Mol Med* 2020; 52: 1475–1485.

27. Choueiri TK, Motzer RJ, Rini BI, et al. Updated efficacy results from the JAVELIN Renal 101 trial: first-line avelumab plus axitinib versus sunitinib in patients with advanced renal cell carcinoma. *Ann Oncol* 2020; 31: 1030–1039.

28. Choueiri TK, Powles T, Burotto M, et al. Nivolumab plus cabozantinib versus sunitinib for advanced renal-cell carcinoma. *N Engl J Med* 2021; 384: 829–841.

29. Motzer R, Alekseev B, Rha S-Y, et al. Lenvatinib plus pembrolizumab or everolimus for advanced renal cell carcinoma. *N Engl J Med* 2021; 384: 1289–1300.

30. Motzer RJ, Rini BI, McDermott DF, et al. Nivolumab plus ipilimumab versus sunitinib in first-line treatment for advanced renal cell carcinoma: extended follow-up of efficacy and safety results from a randomised, controlled, phase 3 trial. *Lancet Oncol* 2019; 20: 1370–1385.

31. Powles T, Plimack ER, Soulières D, et al. Pembrolizumab plus axitinib versus sunitinib monotherapy as first-line treatment of advanced renal cell carcinoma (KEYNOTE-426): extended follow-up from a randomised, open-label, phase 3 trial. *Lancet Oncol* 2020; 21: 1563–1573.

32. Rini BI, Powles T, Atkins MB, et al. Atezolizumab plus bevacizumab versus sunitinib in patients with previously untreated metastatic renal cell carcinoma (IMmotion151): a multicentre, open-label, phase 3, randomised controlled trial. *Lancet* 2019; 393: 2404–2415.

33. Motzer RJ, Tannir NM, McDermott DF, et al. Conditional survival and 5-year follow-up in CheckMate 214: first-line nivolumab plus ipilimumab versus sunitinib in advanced renal cell carcinoma. In: *ESMO annual congress*, 2021. https://www.esmo.org/meetings/past-meetings/esmo-congress-2021.

34. Motzer RJ, Powles T, Atkins MB, et al. Final overall survival and molecular analysis in IMmotion151, a phase 3 trial comparing atezolizumab plus bevacizumab vs sunitinib in patients with previously untreated metastatic renal cell carcinoma. *JAMA Oncol* 2022; 8: 275–280.

35. Haanen JB, Larkin J, Choueiri TK, et al. Efficacy of avelumab + axitinib (A + Ax) versus sunitinib (S) by IMDC risk group in advanced renal cell carcinoma (aRCC): extended follow-up results from JAVELIN Renal 101. *Journal of Clinical Oncology*. 2021; 39 (15 suppl): 4574.

36. Rini BI, Plimack ER, Stus V, et al. Pembrolizumab (pembro) plus axitinib (axi) versus sunitinib as first-line therapy for advanced clear cell renal cell carcinoma (ccRCC): results from 42-month follow-up of KEYNOTE-426. *Journal of Clinical Oncology*. 2021; 39 (15 suppl): 4500.

37. Powles T, Choueiri TK, Burotto M, et al. Final overall survival analysis and organ-specific target lesion assessments with two-year follow-up in CheckMate 9ER: nivolumab plus cabozantinib versus sunitinib in patients with previous untreated metastatic renal cell carcinoma. *Lancet Oncol* 2019; 20: 1370–1385.

38. Choueiri TK, Powles T, Porta C, et al. A phase 3 trial of lenvatinib plus pembrolizumab versus sunitinib as a first line treatment for patients with advanced renal cell carcinoma: overall survival follow up analysis (the CLEAR study). In: *Kidney cancer research summit (KCRS)*, Philadelphia, PA, USA, 7–8 October 2021.
39. Motzer RJ, Tannir NM, McDermott DF, et al. Nivolumab plus ipilimumab versus sunitinib in advanced renal cell carcinoma. N Engl J Med 2018; 378: 1277–1290.

40. Cella D, Choueiri TK, Hamilton M, et al. Health-related quality of life (HRQoL) in previously untreated patients with advanced renal cell carcinoma (aRCC) in CheckMate 214: five-year follow-up results. J Clin Oncol 2022; 40: 307.

41. Atkins MB, Rini BI, Motzer RJ, et al. Pembrolizumab plus axitinib versus sunitinib for advanced renal cell carcinoma. N Engl J Med 2019; 380: 1116–1127.

42. Bedke J, Rini BI and Plimack E. Health-related quality-of-life (HRQoL) analysis from KEYNOTE-426: pembrolizumab (pembro) plus axitinib (axi) vs sunitinib for advanced renal cell carcinoma (RCC). In: EAU20 virtual congress, virtual, 2020.

43. Rini BI, Plimack ER, Stus V, et al. Pembrolizumab plus axitinib versus sunitinib for advanced renal-cell carcinoma. N Engl J Med 2019; 380: 1128–1135.

44. Cella D, Motzer RJ, Suarez C, et al. Patient-reported outcomes with first-line nivolumab plus cabozantinib versus sunitinib in patients with advanced renal cell carcinoma treated in CheckMate 9ER: an open-label, randomised, phase 3 trial. Lancet Oncol 2022; 23: 292–303.

45. Motzer RJ, Porta C, Alekseev B, et al. Health-related quality-of-life (HRQoL) analysis from the phase 3 CLEAR trial of lenvatinib (LEN) plus pembrolizumab (PEMBRO) or everolimus (EVE) versus sunitinib (SUN) for patients (pts) with advanced renal cell carcinoma (aRCC). J Clin Oncol 2021; 39: 4502–4514.

46. Hutson TE, Choueiri TK, Motzer RJ, et al. Post hoc analysis of the CLEAR study in advanced renal cell carcinoma (RCC): effect of subsequent therapy on survival outcomes in the lenvatinib (LEN) + everolimus (EVE) versus sunitinib (SUN) treatment arms. Journal of Clinical Oncology. 2021; 39, (15 suppl): 4562.

47. Gafanov R, Powles T, Bedke J, et al. 669P subsequent therapy following pembrolizumab + axitinib or sunitinib treatment for advanced renal cell carcinoma (RCC) in the phase III KEYNOTE-426 study. Ann Oncol 2021; 32: S694.

48. Motzer RJ, Escudier B, McDermott DF, et al. Survival outcomes and independent response assessment with nivolumab plus ipilimumab versus sunitinib in patients with advanced renal cell carcinoma: 42-month follow-up of a randomized phase 3 clinical trial. J Immunother Cancer 2020; 8: e000891.

49. Choueiri TK, Powles T, Porta C, et al. A phase 3 trial of lenvatinib plus pembrolizumab (LEN+PEMRO) versus sunitinib as a first-line treatment for patients with advanced renal cell carcinoma (aRCC): overall survival follow-up analysis (CLEAR study). In: International kidney cancer symposium, Austin, TX, USA.

50. Regan MM, Jegede OA, Mantia CM, et al. Treatment-free survival after immune checkpoint inhibitor therapy versus targeted therapy for advanced renal cell carcinoma: 42-month results of the CheckMate 214 trial. Clin Cancer Res 2021; 27: 6687–6695.

51. Hammers HJ, Plimack ER, Infante JR, et al. Safety and efficacy of nivolumab in combination with ipilimumab in metastatic renal cell carcinoma: the CheckMate 016 study. J Clin Oncol 2017; 35: 3851.

52. Hodi FS, Chesney J, Pavlick AC, et al. Combined nivolumab and ipilimumab versus ipilimumab alone in patients with advanced melanoma: 2-year overall survival outcomes in a multicentre, randomised, controlled, phase 2 trial. Lancet Oncol 2016; 17: 1558–1568.

53. Antonia SJ, López-Martin JA, Bendell J, et al. Nivolumab alone and nivolumab plus ipilimumab in recurrent small-cell lung cancer (CheckMate 032): a multicentre, open-label, phase 1/2 trial. Lancet Oncol 2017; 18: 883–895.

54. Hellmann MD, Rizvi NA, Goldman JW, et al. Nivolumab plus ipilimumab as first-line treatment for advanced non-small-cell lung cancer (CheckMate 012): results of an open-label, phase 1/2 trial. Lancet Oncol 2016; 17: 1558–1568.

55. Wolchok JD, Kluger H, Callahan MK, et al. Nivolumab plus ipilimumab in advanced melanoma. N Engl J Med. 2013; 369: 122–133.

56. Motzer RJ, Choueiri TK, Powles T, et al. Nivolumab + cabozantinib (NIVO + CABO) versus sunitinib (SUN) for advanced renal cell carcinoma (aRCC): outcomes by sarcomatoid histology and updated trial results with extended follow-up of CheckMate 9ER. J Clin Oncol 2021; 39: 308.

57. Albiges L, Tannir NM, Burotto M, et al. Nivolumab plus ipilimumab versus sunitinib for first-line treatment of advanced renal cell carcinoma: extended 4-year follow-up of the
phase III CheckMate 214 trial. *ESMO Open* 2020; 5: e001079.

58. Apolo AB, Powles T, Burotto M, et al. Nivolumab plus cabozantinib (N + C) versus sunitinib (S) for advanced renal cell carcinoma (aRCC): outcomes by baseline disease characteristics in the phase 3 CheckMate 9ER trial. *Journal of Clinical Oncology*. 2021; 39 (15 suppl): 4553.

59. Tomita Y, Motzer RJ, Choueiri TK, et al. Efficacy of avelumab plus axitinib (A + Ax) versus sunitinib (S) by number of IMDC risk factors and tumor sites at baseline in advanced renal cell carcinoma (aRCC): extended follow-up results from JAVELIN Renal 101. *Journal of Clinical Oncology*. 2021; 39(6 suppl): 302.

60. McDermott DF, Choueiri TK, Motzer RJ, et al. CheckMate 214 post-hoc analyses of nivolumab plus ipilimumab or sunitinib in IMDC intermediate/poor-risk patients with previously untreated advanced renal cell carcinoma with sarcomatoid features. *J Clin Oncol* 2019; 37: 4513.

61. Rini BI, Plimack ER, Stus V, et al. Pembrolizumab (pembro) plus axitinib (axi) versus sunitinib as first-line therapy for metastatic renal cell carcinoma (mRCC): outcomes in the combined IMDC intermediate/poor risk and sarcomatoid subgroups of the phase 3 KEYNOTE-426 study. *Journal of Clinical Oncology*. 2019; 37 (15 suppl): 4500.

62. Choueiri T, Eto M, Kopyltsov E, et al. 660P phase III CLEAR trial in advanced renal cell carcinoma (aRCC): outcomes in subgroups and toxicity update. *Ann Oncol* 2021; 32: S683–S685.

63. Tannir NM, Signoretti S, Choueiri TK, et al. Efficacy and safety of nivolumab plus ipilimumab (N + I) versus sunitinib (S) for first-line treatment of patients with advanced sarcomatoid renal cell carcinoma (sRCC) in the phase 3 CheckMate 214 trial with extended 5-year minimum follow-up. *J Clin Oncol* 2022; 40: 352.

64. Tannir NM, Signoretti S, Choueiri TK, et al. Efficacy and safety of nivolumab plus ipilimumab versus sunitinib in first-line treatment of patients with advanced sarcomatoid renal cell carcinoma. *Clin Cancer Res* 2021; 27: 78–86.